Researchers examine link between tumor mutational burden and response to immune checkpoint therapy
The Medical News,
Predicting how patients will respond to anti-cancer therapies can be vital in informing clinical decisions and improving…
Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors
Overview of attention for article published in JCO Precision Oncology, December 2017
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (93rd percentile)
-
High Attention Score compared to outputs of the same age and source (90th percentile)
Readers on
- mendeley
- 74 Mendeley
